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1. Introduction 
1.1 Oral microbiome 
The oral microbiome is composed of Archaea, Viruses, Bacteria, and Fungi which colonize 
different surfaces of the oral cavity.1 2 Historically, most oral microbiome studies have focused on 
bacteria probably due to their higher abundance in the oral cavity when compared to fungi 3. 
Nevertheless, oral fungal communities (the oral mycobiome) are important and typical 
components of the normal oral microbiota and have been recently shown to be highly diverse 4 5. 
Although the role of most fungal species in oral homeostasis is not fully understood, fungi could 
play a role in oral homeostasis. For instance, it has been shown in an animal model that in the gut, 
fungi are not always associated with disease. On the contrary, their depletion could lead to the 
disruption of the host health6. In the oral cavity, a disruption of the oral mycobiome is associated 
with disease. It has been shown that there is an increased risk of developing oral candidiasis in 
patients with HIV infection, organ transplantation and subjects receiving chemotherapy and 
radiation therapy. 7 8 9 Oral candidiasis can considerably contribute to the morbidity of 
immunocompromised patients, as it could induce pain and burning sensation. In advanced stages 
it can lead to poor nutrition and also compromise the oral epithelial barrier leading to invasive 
infection such as esophagitis or candidemia. 9 
 
1.2. Oral mycobiome 
The genus Candida is the most predominant fungus recovered from the human oral cavity 
via cultivation techniques and it is the most studied genus of the oral mycobiome. In a classic study 
by Young et al. (1951), using cultivation techniques, yeasts were recovered from saliva samples 
in almost half (285) of a large healthy population (584 subjects). From these positive subjects, 
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obtained yeasts were predominantly C. albicans (94%), followed by C. tropicalis (2%), C. 
stellatoides (1%),  and Cryptococcus spp (1%) 10. In a more recent oral mycobiome study, the oral 
rinse collected from 40 healthy young adults was analyzed for detection of yeast and moulds via 
cultivation followed by molecular identification of isolates. Ten of these subjects were also 
evaluated during three sampling periods with 15 days and 6 months between each sampling. To 
avoid any air-borne contamination samples were worked on in a vertical laminar flow hood. This 
group was able to increase the recovery rate of mould (100%) and yeasts (92%) through decreasing 
the incubation temperature to 25°C. The most frequently isolated fungi from the total population 
were Candida (67%), Rhodotorula (75%), Penicillium (85%), Aspergillus (75%), and 
Cladosporium (72.5%). Furthermore, the samples obtained at different time intervals showed 
consistent colonization of yeasts (Candida and Rhodotorula) and moulds (Cladosporium, 
Aspergillus and Penicillum) confirming that these fungi are not transient microbes in the oral 
cavity. 11  
 
A greater number of taxa have been reported to be present in the oral cavity utilizing 
molecular methods, compared to those recovered via cultivation, but it is not clear yet which of 
these taxa are true oral residents. 4 5 Similar to the use of the 16S rRNA gene as a molecular marker 
to survey bacteria, fungal communities can be profiled via the internal transcribed spacer (ITS) 
regions of its nuclear ribosomal RNA allowing a more comprehensive survey of fungal 
communities, including species that are difficult to cultivate. The ITS region derived from a wide 
range of fungal species can be simultaneously amplified using fungal universal primers, then these 
amplicons can provide phylogenetically informative sequence data, especially at lower taxonomic 
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levels. Compared to the ITS2 region, the ITS1 region is more variable and therefore offers more 
discriminatory power. 12 
 
In 2010, Ghannoum et al. characterized the fungal oral microbiome from oral rinses of 20 
healthy subjects using multitag 454 pyrosequencing (MTPS) technique. This group found a total 
of 74 culturable and 11 non-culturable fungal genera with different prevalence among the studied 
subjects. Furthermore, they proposed a basal core mycobiome shared by at least 20% of the study 
participants, in which Candida was the most prevalent as it was found in 75% of the participants, 
followed by Aspergillus (35%), Fusarium (30%), and Cryptococcus (20%). 4  At a later point, this 
core mycobiome was redefined by Dupuy et al. (2014) who developed and validated molecular 
methods for the characterization of the oral mycobiome from samples consisting of unstimulated 
saliva from 6 subjects. Apart from Candida, this group found similar prevalent fungal genera to 
those previously reported by Ghannoum et al. (2010), such as Cladosporium/Davidiella, 
Alternaria/Lewia, Aspergillus/Emericella/Eurotium, Cryptococcus/Filobasidiella, 
Fusarium/Gibberella, and Aureobasidium 5. However, in this study, most of the subjects examined 
showed Malassezia as the most abundant oral mycobiome member. Malassezia was found as a 
prominent member of the oral mycobiome, varying from 13% to 96% relative abundance per 
subject. This was the first study in which Malassezia was reported in the oral cavity. Malassezia 
was not probably reported before by previous molecular studies because its detection requires very 
harsh lysis protocols prior to DNA extraction. 5  
 
Recent unpublished work from the Diaz lab, in a larger cohort, has confirmed that 
Malassezia are commonly seen in the oral cavity, and they were as a matter of fact the most 
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abundant fungi found in the salivary mycobiome of 59 subjects. In this study, fungal communities 
clustered in two groups (or mycotypes) in which the dominant fungus was either Candida or 
Malassezia (Figure 1). Thus, it seems that Malassezia could be indeed an important mycobiome 
member. 
 
 
Fig.1 Clustering of salivary fungal communities of 59 subjects showing the presence of 
two mycotypes. Subjects appear in rows and fungal genera in columns. Heatmap colors represent 
relative abundance as determined via ITS1 sequencing (unpublished data from Diaz Lab) 
 
Although these molecular studies demonstrate that Malassezia species are abundant in the 
oral cavity, this genus has never been recovered by cultivation from human oral samples. 
Therefore, it is still unclear if this and other fungi previously detected via molecular methods are 
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true oral residents.13 Although Malassezia species are cultivable fungi, their isolation requires the 
presence of lipids in the media which previous culture-based studies have not used. 14 
 
1.3. Association of oral mycobiome and disease  
Candida albicans is recognized as the most prevalent Candida species in the oral cavity 
via cultivation. 10 11 5. However, the sole presence of C. albicans does not usually result in disease, 
but it is believed that this is an opportunistic organism taking advantage of the immunosuppression 
of the host to grow. 15 Elderly patients with head and neck malignancies, receiving conventional 
radiotherapy, are one of the most common groups to show Candida overcolonization due to 
induced xerostomic state, concomitant oral mucositis in association to chemotherapeutic drugs and 
difficulties to establish adequate oral hygiene 16 17 18 19. It has been reported that before treatment, 
50% of head and neck cancer patients have detectable oral Candida colonization; however, this 
increases to nearly 70% during active radiotherapy 20. Lalla et al. in a systematic review found that 
the prevalence of oral candidiasis during head and neck radiation therapy (37.4%) was similar to 
that during chemotherapy (38%)9.  
 
In addition, animal model studies have suggested C. albicans could play a role in caries. It 
has been shown that synergism between Streptococcus mutans and Candida albicans may 
contribute to the development of caries lesions with the latter also boosting the cariogenic effect 
of low cariogenic microbiota. 21 22  
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There is no known role for other fungi in oral disease. However, it may be important to 
also understand which oral fungi are associated with health as they might help to keep balance of 
microorganisms in a healthy community. 
 
1.4. Biology of the genus Malassezia 
Malassezia is a lipid-dependent yeast which is found in healthy skin. It has shown 
pathogenic potential through the production of indolic aryl hydrocarbon receptor (AhR) ligands 
such as indolo [3,2-b] carbazole (ICZ),  malassezin and indirubin 23. The activation of the AhR has 
been associated with different diseases such as seborrheic dermatitis and pityriasis versicolor. 24 
In the latter, environmental conditions such as increased temperature and humidity may also play 
an important role in the proliferation of Malassezia and its change into a hyphal morphology. 25 
 
To date, a total of fifteen Malassezia species have been recovered from the human body 26 
27
 and these are: Malassezia furfur, Malassezia japonica, Malassezia obtusa, Malassezia 
yamatoensis, Malassezia globose, Malassezia restricta, Malassezia sympodialis, Malassezia 
dermatitis, Malassezia caprae, Malassezia equina, Malassezia nana, Malassezia pachydermatis; 
Malassezia cuniculi, Malassezia slooffia, and Malassezia arunalokei. These species are found as 
the most prevalent fungi in diverse areas of the human skin such as back, occiput, antecubital fossa 
but not in the foot 28 29 . Interestingly, Malassezia has also been detected in the nasal vestibule 30, 
sinus 31 , respiratory tracts in patients with cystic fibrosis 32, oral cavity 5 and root canal infected 
teeth. 33 
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Skin disorders associated with the presence of Malassezia species include pityriasis 
versicolor, Malassezia (pityrosporum) folliculitis, dandruff / seborrheic dermatitis, atopic 
dermatitis, and psoriasis. 34 In addition, Malassezia has also been identified in blood from 
septicemic neonates receiving lipid supplementation.35 Interestingly, in a molecular study by 
Shelburne et al. (2015), Malassezia was recovered from oral swab samples from a leukemic patient 
with invasive mucormycosis at different time intervals with its higher abundance found in the early 
time point (first 4 days prior to the development of invasive disease). Then, as infection progressed, 
Malassezia decreased in proportion 36. 
 
As highlighted before, Malassezia has a lipophilic and lipid dependent nature and requires 
a lipid-rich medium as they do not possess a complete pathway for synthesis of fatty acids. 26 
However, there is a medium that allows the recovery of Malassezia and also Candida 
simultaneously, but has never been used for cultivation of oral fungi. This chromogenic media 
(CHROMagarTM Malassezia) allows the growth and differentiation of the colonies by colors and 
size. 14 However, up to now, Malassezia has never been recovered from the oral cavity by 
cultivation methods and therefore its role in oral health or its potential involvement in mucosal 
pathologies is still unknown. 
 
1.5. Rationale for this study  
Malassezia have never been recovered by cultivation from oral human samples and the 
only available evidence of their presence in the oral cavity is based on molecular detection. These 
studies have given us valuable information showing Malassezia has a high prevalence compared 
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to any other fungal species in the mouth, but questions regarding the role they could be playing in 
the oral ecosystem are still unresolved. 
 
Comparing cultivation and high throughput molecular approaches to characterize the oral 
mycobiome could confirm the existence of Malassezia in the oral cavity as viable cells. Cultivation 
could also reveal the total load of oral Malassezia since ITS sequencing only reveals relative 
abundance. High throughput characterization of oral samples is nevertheless important since 
certain oral fungi may not be cultivable. Through these complimentary analyses we can therefore 
extend knowledge on the oral mycobiome in particular Malassezia oral colonization patterns. 
 
Therefore, the present study aims to evaluate if oral Malassezia are cultivable. We will 
evaluate the presence of Malassezia using cultivation techniques in comparison to molecular 
methods. We will also compare the recovery of other fungi using CHROMagarTM Malassezia to 
their molecular detection. Fungal colonization patterns will be evaluated in saliva and mucosa 
samples to evaluate possible differences according to site. Our study cohorts will include subjects 
undergoing cancer treatment, and therefore expected to be immunosuppressed and non-cancer 
controls. This will also allow exploration of differences in fungal colonization between cohorts.  
 
1.6. Hypothesis 
 
We hypothesize that by using a lipid-containing medium, Malassezia species can be recovered 
from the oral cavity. 
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We also hypothesize that recovery of fungi will be higher using molecular methods as not all oral 
mycobiome members are cultivable.  
 
We hypothesize that the oral mycobiome follows site specific colonization patterns, and therefore 
there will be a difference in frequency and abundance of fungi between saliva and oral mucosa. 
 
We hypothesize that in accordance to previous studies (preliminary data from Diaz lab), Candida 
species would be the predominant in a subset of subjects, while other group of subjects would have 
predominantly high levels of Malassezia species. 
 
We also hypothesize that the oral mycobiome will differ in subjects undergoing cancer treatment 
from non-cancer controls. 
 
2. Objectives 
2.1. Specific aims 
Aim 1: 
- To compare in a pilot manner the oral mycobiome in subjects receiving cancer treatment and 
non-cancer controls. 
Aim 2: 
- To compare the prevalence of oral fungi as detected molecularly versus fungi detected in 
CHROMagarTM Malassezia via cultivation. 
Aim 3: 
- To compare cultivable fungi between saliva and mucosa. 
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3. Study design and population 
This is a prospective observational study.  
We collected oral mucosa swabs and saliva samples from a total of 25 subjects:  
• Thirteen subjects diagnosed with cancer and undergoing chemotherapy or radiation therapy. 
• Twelve non-cancer subjects recruited from the general population.  
The Cancer subjects were recruited from patients assigned to the Department of Medicine 
Division of Hematology/Oncology UConn Health Center (UCHC). We included this group of 
subjects since they are prone to oral yeast proliferation, colonization and infection  18 19 
The Non-cancer subjects were recruited through flyers posted at Uconn Health. The IRB 
approval number of this study was 141622. 
 
3.1. Inclusion and exclusion criteria 
3.1.1. Inclusion criteria 
• Cancer cohort: patients with hematological malignancies, head neck and solid tumors 
undergoing chemotherapy treatment alone or in combination with head neck radiotherapy at 
the Department of Medicine Division of Hematology/Oncology UCHC; 
• Non-cancer cohort: patients not diagnosed with cancer; 
• Both groups: patients 18 years old or older belonging to any ethnical group or gender and 
who are proficient in English; 
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3.1.2. Exclusion criteria 
• Subjects who, at screening appointments, do not fulfill the inclusion criteria as described 
above; 
• Subjects diagnosed with non-cancer-related systemic diseases and conditions characterized 
by xerostomia, or with non-cancer-related conditions that may affect mucosal health or 
predispose to fungal infections (e.g. Sjogren’s Syndrome, AIDS, diabetes) and/or subjects 
taking immunosuppressants (not related to their cancer treatment); 
• Pregnant subjects. 
 
3.2. Clinical study procedures and sample collection 
3.2.1. Enrollment:  
• Cancer subjects 
For each of the thirteen cancer subjects, saliva and oral swabs were collected prior, or during 
the course of chemotherapy treatment alone or in combination with head neck radiotherapy at 
any visit during the course of treatment.  
This study only comprised one visit, which was part of the regular schedule for cancer 
treatment at the Department of Medicine Division of Hematology/Oncology UCHC. Study 
procedures only added 15-30 minutes of additional visit time. This study represented a minimal 
risk to volunteers due to the non-invasive nature of the oral examination, oral swabs and saliva 
collection. Although every subject was offered compensation for their time, some of them 
refused to be compensated for their participation in the study. 
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Dr. Cardenas conducted the enrollment of study subjects at the Department of Medicine 
Division of Hematology/Oncology UCHC. This enrollment was based on the inclusion and 
exclusion criteria described above. Before starting treatment, the attending oncologist, Dr. 
Hegde, approached eligible subjects (based on inclusion/exclusion criteria) and asked if he/she 
would be interested in hearing about the study. If the answer was positive, then Dr. Cardenas 
explained the study design and objectives to the subjects, as well as addressed his/her questions 
and concerns.  
 
• Non-cancer subjects 
For each of the twelve non-cancer subjects, saliva collection and oral swabs were collected by 
Dr. Cardenas at the Dental Clinical Research Center (DCRC) at the UCHC in one visit. 
Interested subjects were asked (via flyers) to contact staff at the DCRC to schedule an 
appointment. The DCRC staff asked the subject some questions over the phone to confirm 
eligibility and then scheduled a visit. The study procedures took between 15 to 30 minutes. 
Subjects received compensation for their participation in the study. Healthy subjects which 
were employees or students at UCHC were informed that participating in this study would not 
affect their role at UCHC. 
 
3.2.2. Informed consent 
If the subject agreed to participate in the study, an informed consent document was provided and 
explained to the patient. 
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3.2.3. Demographic and medical data collection  
Data collected included demographics, medical history (including cancer diagnosis and treatment), 
oral examination (including assessment of oral mucositis via the WHO scale, presence of 
candidiasis or other mucosal finding), number of teeth, teeth replaced with fixed or removable 
prosthesis and number of teeth with visible cavitated carious lesions. All subjects were asked if 
they have had a history (at any time in their lives) of antifungal treatment for any condition. For 
cancer subjects, additional data from their medical chart was extracted from the subject’s medical 
record and entered in the appropriate case report forms (CRFs) for this study.  
 
3.2.4. Saliva collection 
Unstimulated saliva was collected following the protocol described by Navazesh and Kumar 37 
with the exclusion of rinsing the mouth with deionized water for five minutes before saliva 
collection. Unstimulated saliva was collected by having subjects expectorate into a 50mL sterile 
conical tube for a 5-minute period. The salivary collection procedure was performed as follows: 
- Subjects were instructed to minimize movement during collection, especially the movement of 
the mouth and to keep their eyes open during collection. 
- Subjects were asked to swallow to clear the mouth of saliva, then not to swallow again until the 
end of the timed collection (5 minutes).  
- When the timer started, subjects leant forward over the collection vial (50 mL sterile 
polycarbonate vial) allowing the saliva to flow freely from their slightly opened mouth into the 
vial for up to 5 minutes.  
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- Subjects with xerostomia due to the cancer treatment were instructed to try to collect as much 
saliva as possible. 
 
3.2.5. Oral examination 
Soft tissue examination was performed using diagnostic dental instruments and the World Health 
Organization (WHO) scale which grades oral mucositis as follows:  
Grade 0 = No oral mucositis  
Grade 1 = Erythema and soreness  
Grade 2 = Ulcers, able to eat solids  
Grade 3 = Ulcers, requires liquid diet (due to mucositis)  
Grade 4 = Ulcers, alimentation not possible (due to mucositis)  
The presence/absence of oral candidiasis (for example in the form of pseudomembranous 
candidiasis such as white wipable lesion which after scrapped off reveals a raw erythematous 
surface), was also evaluated. 
Presence of mucosal lesions not classified as oral mucositis were also described (for instance the 
presence of erythematous tissue due to denture stomatitis) 
The presence/absence of visible caries lesions, number of teeth, number of implants and a report 
of all prosthetic restoration (crowns, removable dentures, orthodontic retainer) were also 
recorded.  
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3.2.6. Oral swab collection  
One sterile oral swab sample was collected from right and left buccal mucosa and from the 
tongue dorsum for culturing studies. This swab was placed into a 2mL vial with 1mL of sterile 
phosphate buffered saline (PBS). After pressing the swab against the tube walls to release the 
sample, the swab was removed. Oral swabs were not collected for molecular evaluation as 
previous studies in the Diaz Lab have shown that in many instances it is not possible to obtain 
ITS1 amplicons from mucosal swabs probably due to low fungal biomass.  
 
3.3. Microbiological laboratory procedures 
Collected saliva and swab samples were immediately transported to Dr. Diaz’ laboratory where 
they were processed: 
• For cultivation analysis: Half of the saliva sample and one swab sample were used for 
plating onto CHROMagarTM Malassezia plates. After growth, colonies were counted, 
passaged, stored and DNA was extracted from them at a later point for their identification 
via Sanger sequencing. 
• For molecular analysis: Half of the saliva sample was spun down in the centrifuge at 
6,000 rpm x 10 minutes. Supernantant was removed and pellet was stored at -80ºC for 
later molecular characterization.  
 
3.3.1. Cultivation analysis 
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CHROMagarTM Malassezia medium  supplemented with Glycerol at 2 g/L and Tween 40 at 10 
g/L (as recommended by the manufacturer) was used for detection of Candida, Malassezia and 
possibly other mycobiome members via cultivation. Saliva and mucosa swabs samples were 
processed in the following manner: 
• Samples were spun down in the centrifuge at 4,200 rpm x 10 minutes. 
• Pellet was resuspended in 200 uL of sterile PBS for a 5x concentrated sample, of which 
an aliquot plated. 
• The sample was then resuspended to its original volume (1 mL) followed by plating of 
undiluted samples and dilutions to 10-1 and 10-2. 
• For incubation purposes, plates were placed in a ziplock plastic bag with wet paper 
towels to recreate a humid environment.  
• Then, bags were incubated in a 32ºC room for 7 days. 
• After 7 days, CFUs were counted and 20% of the colonies obtained including all 
morphologically distinct colonies were re-streaked.  
• After 3-7 days of incubation, representative isolates were recovered and placed in 2 
mLvials: Suspected Malassezia strains and unknown (difficult to identify) in mDixon 
broth (420 uL) with 30% glycerol (180 uL) and suspected Candida strains in YPD broth 
(420 uL) with 30% glycerol (180 uL).  
Strains were stored as frozen stocks in -80ºC. 
 
3.3.1.1. Regrowth of representative isolates for DNA extraction and identification 
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One isolate from each type of colony found in saliva and each type of colony found in mucosa of 
each subject was selected to be revived utilizing CHROMagarTM Malassezia medium  (as 
described above). For this purpose, each glycerol stock was processed in the following manner: 
• Strain was streaked for isolation in a new plate, and incubated under the conditions 
described above. 
• After 2 – 4 days, the revived isolate was spreaded in a new plate. If more than one isolate 
with different characteristics was found, then each of them was replated separately. 
• After 2-4 days of incubation, the isolates were recovered and resuspended in 300 uL PBS.  
• Samples were spun down in the centrifuge at 10,000 rpm x 10 minutes. 
• PBS was then discarded and the pellet was either processed immediately as indicated 
below (next section) or stored at -80ºC for later processing. 
 
3.3.1.2. gDNA extraction from individual isolates  
The chosen isolate pellets were resuspended in 200 uL TE. Next, 400 uL Yeast Cell Lysis Buffer 
from the MasterPure™ Yeast DNA Purification Kit (cat #MPY80200, Epicentre, Madison, WI) 
and 35 uL of proteinase K (from Invitrogen) were added to the mix and vortexed. This mix was 
then incubated at 37°C for 1 hour with shaking. After an hour, 635 uL of the mix were placed into 
a Matrix Y  tube. These tubes contain 0.5 mm diameter Yttria-Stabilized Zirconium Oxide beads 
which have high density and extremely high hardness. Ideal to break tough cell walls, its smooth 
surface minimizes shearing FastPrep® Lysis Beads & Matrix Tubes for Sample Disruption 
(LYSING MATRIX Y (116960050) - MP Biomedicals, Santa Ana, CA). The sample was 
homogenized in a FastPrep® 24 instrument three times at speed 6 m/s for 30 seconds while resting 
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30 seconds between bead beating. The sample was then put to incubate for 30 min at 65°C in the 
heat block. Thirty minutes after, a short spin was given to the tubes before opening (14,000 x 10 
seconds in the centrifuge). The lysate was transferred to a clean 2 mL eppendorf tube and 35 μL 
of RNase A (Invitrogen PureLink Genomic DNA Kit, cat#K1820-02, Invitrogen, Carlsbad, CA) 
was added, mixed well by brief vortexing, and incubated at room temperature for 2 minutes. 
Following lysis procedures, PureLink Genomic Lysis/Binding Buffer was added and mixed well 
by brief vortexing to obtain a homogenous solution and incubated at room temperature for 2 mins. 
Later, 96–100% ethanol was added to the lysate. Mixed well by vortexing for 5 seconds to yield a 
homogenous solution. 
Aproximately 700 μL of the prepared lysate described above, was placed into a single PureLink 
Spin Column.  The column was centrifuged at 10,000×g for 1 minute at room temperature. At this 
point, the collection tube was discarded and the spin column was placed into a clean PureLink 
Collection Tube. Then the remaining lysate was placed into the column and the previous step was 
repeated.  
Next, 500 μL Wash Buffer 1 prepared with ethanol was added to the column. This column was 
then centrifuged at room temperature at 10,000 ×g for 1 minute. Then, the collection tube was 
discarded and the spin column was placed into a clean PureLink collection tube. Next, 500 μL 
Wash Buffer 2 prepared with ethanol was added to the column. This column was then centrifuged 
at maximum speed for 3 minutes at room temperature. The liquid was discarded from the collection 
tube. The column was placed back in the collection tube and dried centrifuging it at maximum 
speed for 3 minutes at room temperature. Then the collection tube was discarded. 
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Later, the spin column was placed in a sterile 1.5 mL microcentrifuge tube and 25 μL of 
PureLinkGenomic Elution Buffer was added. After incubation at room temperature for 1 minute 
the column was centrifuged at maximum speed for 1 minute. To recover more DNA, a second 
elution step was performed using the same elution buffer volume as first elution in the same 1.5 
mL microcentrifuge tube. The purified DNA was stored at –20°C. 
 
3.3.1.3. gDNA cleaning 
To clean the DNA, we took 40 uL of the previously stored DNA and placed it in a new 2 ml tube. 
Next, 32 uL buffer AL were added and vortexed to homogenize, followed by addition of 32 uL of 
ethanol (molecular grade). This mixture was pipeted into DNeasy Mini spin column placed in a 2 
ml collection tube (Qiagen blood and tissue kit), and centrifuged at 8000 rpm for 1 min. The 
DNeasy Mini spin Column was placed in a new 2 ml collection tube. Next, 500 uL buffer AW1 
was added and centrifuged for 1 min at 8000 rpm. The DNeasy Mini spin Column was placed in a 
new 2 ml collection tube and 500 uL of buffer AW2 added, and centrifuged for 3 min at 14,000 
rpm, followed by another centrifugation for 3 min at 14,000 rpm to dry DNeasy membrane. The 
column was placed in a new 2 ml vial and eluted in EB Elution buffer in the same volume than 
original sample. DNA concentration was then measured using a Nanodrop Instrument. 
 
3.3.1.4. Amplification of ITS1 region for molecular identification of isolates via Sanger 
sequencing 
The ITS1 region was amplified by PCR and products sequenced via Sanger methods to 
confirm the identity of each isolate. The primers used amplified the ITS1 region (Segre F:  5’-GTA 
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AAA GTC GTA ACA AGG TTT C-3’ and Segre R:  5’-GTT CAA AGA YTC GAT GAT TCA 
C-3’). Tm~50ºC, Amplicon size: 292bp. 29 
 
To prepare 25 uL PCR reaction volumes for each sample we used: 14.3 uL PCR water, 0.2 
uL of Segre forward [0.4 uM] and Segre reverse [0.4 uM] primers, 0.2 uL Accuprime Taq, 2.5 uL 
of 10x Accuprime Buffer II [1x] and 4 uL of sample DNA. We duplicated each sample for the 
PCR reaction following the protocol mentioned above.  
 
In addition to the samples obtained, we included each time a negative control for the DNA 
extraction (TE buffer) and a negative control for the PCR reaction (water). PCR reactions were 
run at 95 °C for 120 seconds, followed by 35 cycles of 95 °C for 20 seconds, 56 °C for 30 seconds, 
and 68°C for 60 seconds and a final extension at 4 °C.  
 
Duplicated PCR products were evaluated by agarose gel electrophoresis. 1 uL of 6x gel 
loading dye, 1 uL of 100bp DNA Ladder from BioLabs ® Inc. (NEB #B7025) combined with 4uL 
of Molecular grade water was used at the ladder site. Samples (5uL) in combination of 1uL of 6x 
gel loading dye were also loaded and run in a 1.2% agarose gel for 35 minutes at 100 mV. Once 
the presence of the products was confirmed at approximate 292 base pairs, then the duplicated 
PCR reactions were combined and cleaned.  
 
3.3.1.5. Cleaning PCR products 
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To clean the PCR products, we took 80 uL of the PCR reactions per each sample and mixed 
it with 5 volumes of Buffer PB QIAquick® PCR Purification Kit (QIAgen, Cat No./ID: 28104, 
Germantown, MD) in a new 2 mL Eppendorf vial. Then, the mix was placed into a QIAquick 
column and centrifuged for 60 seconds at 10,000 RPM. The flow-through was discarded and the 
QIAquick column was placed back in the same tube. Later, 750 uL of Buffer PE was added to the 
QIAquick column and centrifuged for 60 seconds at 10,000 RPM. The flow-through was discarded 
and the QIAquick column was placed back in the same tube. To remove any residual wash buffer, 
the column was centrifuged one more time for 1 minute. Then, the QIAquick column was placed 
in a clean 1.5 mL microcentrifuge tube. To elute DNA, 30uL of elution buffer was added in the 
center of the QIAquick membrane. The column was left to stand for 1 minute and then it was 
centrifuged. DNA concentration was then measured using a Nanodrop Instrument. The recovered 
DNA was then stored in a -20 °C. 
 
3.3.1.6. Dilution for sequencing 
To dilute the cleaned PCR products for sequencing, each sample was diluted to a 
concentration of 1 ng/uL using buffer EB in a new 1.5 mL Eppendorf vial. 
Then, 10 uL of the diluted PCR product was placed in a 0.2 mL PCR microtube and mixed 
with 5 uL of the primer Segre F or Segre R separately (Primers were in a 5 uM concentration). 
Samples were sent for Sanger sequencing to Genewiz laboratories (GENEWIZ, South Plainfield, 
NJ). 
 
3.3.1.7. Sequence assembly and identification 
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In order to assembly forward and reverse ITS1 sequences, we used CodonCode aligner 
v.8.0.1. software. The F and R files were opened in the Aligner. The ends of these two files were 
clipped. This allowed us to clip low quality bases from the sequence. Then we assembled them 
and exported them as a consensus sequences. Then, we utilized the NCBI’s BLAST tool 
(www.blast.ncbi.nlm.nih.gov), selecting “nucleotide Blast”. The sequence of the sample was 
introduced. We excluded uncultured/environmental and left any other parameters as default. We 
collected the following data: Query cover, E value, Identity and Accession number. This 
information was transferred to a spreadsheet in excel.  
 
All our samples had a Query cover equal or greater to 98% and all of them had identity 
equal of higher to 97% (for the later please note that only one sample had 97% in identity value, 
the rest of them were in the range of 99% and 100%). Using this information, the highest match 
was selected to identify the isolate.  
 
3.3.2. Molecular mycobiome analysis 
For detection of oral fungi via a direct molecular approach (mycobiome characterization): 
•  DNA was extracted from frozen saliva pellets using the same bead-beating method already 
described in section 3.3.1.2. and 3.3.1.3. 
• Primers covering the ITS1 region were used for amplification to construct libraries.  
• ITS1 libraries were bidirectionally sequenced using MiSeq Illumina v3 reagents. 
• For analysis of ITS1 reads, reads were processed in Mothur, and sequences classified 
against a reference database to a genus level.  
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• Candida and Malassezia sequences were also classified to a species level using a reference 
phylogenetic tree. 
 
3.3.2.1. Library preparation 
The ITS1 was amplified from purified genomic DNA using primers containing Illumina 
adapters and Segre F (5′-GTAAAAGTCGTAACAAGGTTTC-3′) and Segre R (5′-
GTTCAAAGAYTCGATGATTCAC-3′). PCR conditions were: 2.5 μl 10X AccuPrime Buffer II, 
0.2 μl Accuprime Taq, 2 μl of each primer (5 μM), and 4 μl of DNA. Samples were run in duplicate 
at the following PCR conditions: 95 °C for 120 seconds, followed by 35 cycles of 95 °C for 20 
seconds, 56 °C for 30 seconds, and 68°C for 60 seconds and a final extension at 4 °C. PCR products 
of duplicates were pooled together and visualized by electrophoresis in agarose gels as decribed 
above. Pooled samples were purified using the AMPure XP-PCR Purification Kit (Agencourt), 
and quantified using QuantIT dsDNA High-Sensitivity Assay Kit. Purity and amplicon length were 
evaluated with Experion DNA kit (Biorad) and equal volumes of 4 nM samples were pooled 
together. The pooled library was mixed with 14% of PhiX and sequenced on an Illumina MiSeq 
platform using v3 reagents according to manufacturer’s indications. 
 
3.3.2.2. Sequence classification and analysis. 
Reads were pre-processed and chimaeric sequences removed using MOTHUR 38. 
Taxonomic classification was performed using a modified version of a previously generated 
custom fungal ITS1 reference database 29 . Candida and Malassezia ITS1 reads were speciated by 
the process previously described by Findley et al. (2013). A curated database including only 
Candida and Malassezia sequences that were previously extracted from the original data-set was 
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generated. This manually curated database was used for phylogenetic classification of Candida 
and Malassezia reads via the pplacer software package 39 considering a likelihood score higher 
than 0.65. The software R was used to generate plots representing relative abundance of fungal 
genera/species, alpha and beta diversity. 
 
3.4. Data analysis 
Chi-square was used to compare differences in gender, ethnicity, presence of removable 
prosthesis, history of usage of antifungals, history of pseudomembranous candidiasis, denture 
stomatitis and oral mucositis between the cancer and non-cancer arms. T-test was used to compare 
differences in age, number of teeth and number of teeth with caries between these two groups. 
Differences in prevalence of salivary fungal genera and species detected via cultivation in cancer 
and non-cancer controls were compared via Chi square and Fisher test. Differences in abundance 
of fungal load via cultivation between saliva samples obtained from cancer and non-cancer 
subjects were compared via Mann-Whitney U test. Also, this test was used to compare the 
abundance of salivary fungal genera and species via cultivation between cancer and non-cancer 
control, and to compare the salivary fungal richness between cultivation and molecular detection. 
McNemar tests were used to compare subjects positive for fungi via cultivation and molecular 
analysis. To compare the prevalence of genera detected by cultivation and molecular methods. To 
compare Candida spp. and Malassezia spp. detected by cultivation and molecular methods, to 
compare number of saliva and mucosal samples positive for fungi, to compare the prevalence of 
genera in saliva and swab samples and to compare prevalence of species in saliva and swab 
samples. 
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Differences in Richness and Diversity of taxa detected molecularly were compared via Mann-
Whitney.  
A P value of <0.05 was considered significant for all the above referred tests.  
Clustering analysis was used to evaluate if the subjects enrolled in this study clustered based upon 
their cancer diagnosis (cancer or non-cancer). 
Differences in the relative abundance of fungi between cancer and controls were evaluated via 
LEfSe (Segata et al. 2011)40.   
 
4. Results 
4.1 Characteristics of enrolled subjects 
Twenty-four subjects out of 25 enrolled completed the study. One subject from the cancer 
arm was excluded from the study due to reduced salivary flow, which prevented saliva sample 
collection. This subject from the cancer arm was a 65 years old female diagnosed with squamous 
cell carcinoma of the right cheek and received radiation therapy for 7 weeks approximately 3-years 
prior this current study, therefore she still presented with reduced salivation.  
 
Although we were able to collect saliva and mucosal samples from 24 subjects (100% of 
our study population), an additional subject from the non-cancer arm was excluded from the 
molecular data analysis due to the low number of counts in the sequencing analysis. However, we 
included this subject for cultivation analysis since we were able to grow colonies from both saliva 
and mucosal samples. These colonies were later identified as Malassezia sympodialis. This subject 
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from the non-cancer arm was a 50-year old female in good overall health condition and history of 
thrush after receiving treatment for diverticulitis 2-months prior enrollment in the present study.  
 
The demographic characteristics of the 24 subjects which completed the study are shown 
on Table 1. There were significant differences between the cancer and non-cancer arms in terms 
of age (p<0.001), gender (p=0.013) and number of teeth (p=0.014). The average age of the total 
subjects was 50 ± 18 years old. However, the cancer arm enrolled subjects older in age as they 
were in average 64 ± 9 years old compared to the non-cancer arm with 35 ±12 years old (p < 
0.001). 
 
In the present study, our population was represented by the following race/ethnicity: White, 
Black and Indian with no differences in their distribution between cancer and non-cancer subjects. 
The cancer arm had less number of teeth compared to the non-cancer arm (p=0.014). There were 
more users of removable prosthesis among the cancer arm compared to the non-cancer arm but 
this variable was not significant. (p=0.158). In addition, the number of teeth with active carious 
lesions were not significant between the arms (p=0.374).  
 
Three patients reported a history of usage of either Nystatin or “magic wash”, which is a 
mixture of ingredients such as diphenhydramine, viscous lidocaine, antacid, nystatin, and 
corticosteroids  41, prior or at the time this study was being conducted. Two of these patients were 
in the cancer arm (16.67%) and one in the non-cancer arm (8.33%). 
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Evidence of mucosal lesions in the form of denture stomatitis, mucositis or oral candidiasis 
was found on 33% of the subjects. Among these, pseudomembranous candidiasis was observed in 
one subject from the cancer arm as a wipeable white lesion on the lateral side of the tongue.  
 
Four patients undergoing chemotherapy presented with oral mucositis degree 1 (WHO 
scale), one patient undergoing chemotherapy in combination of H&N radiation in his 4th week of 
treatment developed oral mucositis degree 1 (WHO scale) and one patient who previously received 
H&N radiation and was receiving chemotherapy at the time of examination presented a degree 3 
(WHO scale) oral mucositis. One subject from the non-cancer arm was using an orthodontic 
retainer for 3 weeks at the time of the examination. This patient presented erythematous epithelium 
underneath his retainer thus he was included in the denture stomatitis group.  
 
 
Table 1. Demographics. Statistical difference p value highlighted in bold. Data represent mean 
+/- SD and range in brackets, or number of subjects with percentage in parenthesis. 
 
4.2 Results related to Aim 1 
Cancer	(12	subjects) Non	Cancer	(12	subjects)
mean	+/-	SD mean	+/-	SD
Age 64.25	+/-	9.38	[49-78] 34.83	+/-	12.43	[23-54] <0.001	(t-test) 49.54+/-18.37	[23-78]
Gender	male	(%) 10	(83.33%) 4	(33.33%) 0.013	(chi	square) 14	(58.33%)
Ethnicity	white	(%) 11	(91.67%) 8	(66.67%) 0.158	(chi	square)	 19	(79.17%)
Number	of	teeth 17.75	+/-	11.20	[0-30] 26.92	+/-	1.89	[23-28] 0.014	(t	test) 22.33	+/-	9.25	[0-30]
Removable	
prosthesis	(%)
Number	of	teeth	with	
caries
Hx	of	antifungals 2	(16.67%) 1	(8.33%) 0.500	(chi	square) 3	(12.5%)
Pseudomembranous	
candidiasis
Denture	stomatitis 0	(0%) 1	(8.33%) 0.500	(chi	square) 1	(4.16%)
Oral	Mucositis	 6	(50%) 0	(0%) 0.007	(chi	square) 6	(25%)
Variable p	value Total	(24	subjects)
4	(33.33%) 1	(8.33%) 0.158	(chi	square) 5	(20.83%)
1.17	+/-	1.82	[0-6] 1.83	+/-	1.62	[0-5] 0.374	(t	test) 1.50	+/-	1.76	[0-6]
1	(8.33%) 0	(0%) 0.500	(chi	square) 1	(4.16%)
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The first aim of this thesis (Aim 1) was to compare in a pilot manner the oral mycobiome 
in subjects receiving cancer treatment and non-cancer controls. Although the study was not 
powered for this analysis, we first wanted to evaluate whether the oral mycobiomes of cancer and 
non-cancer groups showed major differences.  
 
We first compared the oral mycobiome between the cancer arm and the non-cancer arm 
via molecular methods finding no significant difference between these two groups with regards to 
their richness and diversity (Figure 2).  
 
Figure 2. Richness (Fig2A) and Diversity (Fig2B) between the cancer and the non-cancer arm. 
Differences in richness and diversity were evaluated via Mann-Whitney rank tests. 
 
We then used clustering methods, to evaluate if cancer and non-cancer subjects separated 
into two distinct groups. A cluster dendogram utilizing transformed relative abundances of the 
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most dominant taxa (with at least 1% abundance in at least one sample) demonstrated that the 
cancer group and healthy group did not cluster separately. (Figure 3). 
 
Figure 3. Clustering of salivary mycobiome communities. Cluster dendogram using transformed 
relative abundances of taxa represented at at least 1% in at least one sample. Two clusters are 
observed but they do not correspond to cancer and non-cancer groups. C=cancer and NC=non-
cancer. 
 
Following this, a heatmap was done to visualize the distribution of fungi in each sample 
(Figure 4). As evident in Fig. 4 the two different types of communities (two clusters) show taxa 
with different dominance. In one cluster Candida is the most abundant genus (C1) and, in the 
second group (C2) Malassezia is the dominant genus. 
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Figure 4. Clustering and distribution of fungi in salivary mycobiome communities. Graph shows 
a cluster dendogram and heatmap depicting transformed relative abundances for major mycobiome 
taxa (only taxa represented in at least 1% in at least one sample).   
 
We next tested which taxa were different in relative abundance between cancer and non-
cancer subjects. There was enrichment of only 2 fungi in the control group compared to the cancer 
group, and these were Rhodotorula genus and Candida parapsilosis. (Figure 5). 
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Figure 5. Fungi enriched in the control group, as evaluated via LEfSe (Segata et al. 2011) 40  
 
Next, we compared the salivary fungal load between the cancer and the non-cancer arm via 
cultivation methods and we found that there was not a significant difference in cultivable load 
between these two arms (Figure 6).  
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Figure 6. Salivary fungal load via cultivation. Data represent the total abundance (Log10 
CFU/mL of saliva) per subject and differences between cancer and non-cancer were evaluated 
via Mann Whitney U test. Bars represent the median and whiskers indicate the standard 
deviation. 
 
From the six genera detected by cultivation, the most prevalent and also the only genus 
found in both cancer and non-cancer subjects was Candida. Malassezia genus was found only in 
the cancer arm via cultivation, while Pichia, Rhodotorula, Cryptococcus and Exophiala were 
found in the non-cancer arm only, but none of them showed a statistically significant difference in 
prevalence (Table 2). 
 
 
Table 2. Salivary fungal genera detected via cultivation in cancer and non-cancer controls. Data 
represent percentage of subjects positive. Differences in frequency of detection were evaluated 
via Chi square test (for Candida) and Fisher test (for the remaining genera).  
 
In terms of abundance, Candida was the most abundant taxon in both groups, followed by 
Malassezia in the cancer arm, and Pichia in the non-cancer arm. (Table 3) 
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Table 3. Abundance of salivary fungal genera via cultivation in cancer and non-cancer controls. 
Data represent the total abundance as CFU/mL. Data represent mean ± SD and rage in brackets. 
Differences were evaluated via Mann Whitney U test. 
 
In a species-level analysis, Candida albicans was the most prevalent in the cancer arm and 
in the non-cancer arm compared to other species. In addition, it was the only species to be present 
in both groups. In contrast, C. parapsilosis had a presence only in the non-cancer arm and this was 
statistically significant (p=0.037). Besides the presence of Candida albicans in the cancer arm, 
two additional species were found: Candida glabrata and Malassezia sympodialis. In the non-
cancer arm, six additional species besides C. albicans were found: Pichia guillermodii, 
Rhodotorula mucilaginosa, Rhodotorula species LK1109, Cryptococcus albidosimilis and 
Exophiala dermatitidis. (Table 4) 
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Table 4. Species of salivary fungi detected via cultivation in cancer and non-cancer controls. 
Data represent percentage of subjects positive. Differences in frequency of detection were 
evaluated via Fisher test. Statistical difference p value highlighted in bold. 
 
In terms of species abundance, Candida parapsilosis was the most abundant species in the 
non-cancer arm and it had a significant difference (p=0.025) compared to the cancer arm. In the 
cancer arm, the cultivable mycobiome was dominated by Candida glabrata. (Table 5) 
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Table 5. Abundance of salivary fungal species via cultivation in cancer and non-cancer controls. 
Data represent the total abundance as CFU/mL. Differences were evaluated via Mann Whitney U 
test. Statistical difference p value highlighted in bold. 
 
Overall these results show that via molecular methods the cancer and the non-cancer arms 
did not cluster apart; however, they clustered by the dominance of the genera Candida or 
Malassezia. In addition, it was found that Rhodotorula and Candida parapsilosis were more 
enriched in the non-cancer group, being the latter more significantly prevalent and abundant 
utilizing cultivation methods in this group as well. Furthermore, via cultivation there were no 
significant differences on both arms in terms of fungal load or significant differences in the 
prevalence and abundance at the genus level. 
 
In conclusion, and contrary to what we anticipated, only small differences were observed 
in the oral mycobiome of cancer and non-cancer subjects. Although cultivation detected less taxa 
than the molecular approach, the results were congruent with both methods showing enrichment 
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of C. parapsilosis in controls. Both methods allowed detection of Malassezia, but its prevalence 
and abundance did not differ between cancer and non-cancer subjects.   
 
4.3 Results related to Aim 2 
The second aim of this thesis (Aim 2) was to compare the oral mycobiome as detected 
molecularly and via cultivation. To do this, we first compared the percentage of patients positive 
for fungal colonies identified via cultivation and molecular methods (Figure 7). Via cultivation 
methods a total of 18 (out of 24) subjects were positive for fungal colonies in saliva. Via molecular 
methods, only one subject was not positive. Although molecular methods seemed to be more 
sensitive for detection of the oral mycobiome compared to cultivation methods, our results showed 
that there was not a significant difference between the two methods (p=0.4861). 
 
 
Figure 7. Subjects positive for fungi via molecular and cultivation. Bars represent percentage of 
subjects with detectable fungi. Differences were evaluated via McNemar test. 
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Since the results presented in Aim 1 showed that the cancer and the non-cancer arms did 
not cluster into two different groups based on their cancer diagnosis, we decided to merge these 
two arms into a single group to compare the detection of fungi via molecular versus cultivation 
methods. 
 
Twenty-three subjects were included for the present analysis. Via molecular methods, 
forty-nine genera were found as the most prevalent in 23 subjects (prevalence >10%). Candida 
and Malassezia were the most dominant genera in the studied population (Table 6). 
 
 
Table 6. Most frequently detected salivary fungal genera via sequencing. Data represent 
percentage of subjects positive, and mean ± SD relative abundance. 
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From all the genera detected among the studied subjects, there was a notorious dominance in terms 
of relative abundance of Malassezia and Candida, followed by Rhodotorula and Saccharomyces. 
(Table 6 and Figure 8)  
 
Figure 8. Relative abundance of salivary fungal genera detected molecularly by subject. 
 
At the species level, ten Malassezia sp. and 7 Candida sp. were identified. The most 
prevalent (above 80%) Malassezia species were Malassezia restricta, Malassezia sympodialis and 
Malassezia globosa. None of the Candida species reached the 80% prevalence, and only two 
species were prevalent above 50%: Candida albicans, followed by C. parapsilosis (Table 7 and 
8). 
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Table 7. Malassezia species detected via sequencing. Data represent percentage of subjects 
positive and relative abundance.  
 
Table 8. Candida species detected via sequencing. Data represent percentage of subjects positive 
and relative abundance.  
 
Via cultivation, six genera and nine species were detected. The most prevalent was Candida 
albicans and the most abundant was Candida glabrata.  (Table 9) 
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Table 9. Salivary fungi detected via cultivation. Data represent percentage of subjects positive 
and total abundance.  
 
Furthermore, the number of genera per subject detected via molecular methods surpasses 
the fungal richness detected via cultivation methods, ranging from 9 to 96 the number of genera 
detected for the former and 0 to 3 for the latter. (Figure 9). 
 
 
Figure 9. Comparison of salivary fungal richness (number of genera) by cultivation and 
molecular detection. Differences were evaluated via Mann Whitney test.   
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When we compared both methods of detection, we were able to distinguish only six 
common genera such as Candida, Malassezia, Pichia, Rhodotorula, Exophiala and Cryptococcus.  
Furthermore, the molecular method significantly detected the genera described above (with the 
exception of Pichia and Exophiala) in more patients compared to cultivation methods. (Figure 10) 
 
 
Figure 10. Comparison of prevalence of genera detected by both cultivation and molecular 
methods. Data represent percentage of subjects positive.  Differences were evaluated via 
McNemar test. 
 
At the species level, we compared Candida versus Malassezia species. Strikingly, our 
results show that although Malassezia species were predominant in the oral mycobiome, they were 
not found via cultivation methods except for Malassezia sympodialis with a prevalence of 8.7% (2 
subjects). (Figure 11) 
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Figure 11. Comparison of the five more prevalent Candida sp and Malassezia sp detected by 
cultivation and molecular methods. Data represent percentage of subjects positive.  Differences 
were evaluated via McNemar test. 
 
Overall, these results show that more taxa were detected via molecular methods than by 
cultivation, with Candida species and Malassezia spp as the most prevalent and abundant species 
found molecularly in all the subjects. Candida were the most prevalent and abundantly found via 
cultivation compared to the other five genera detected. There were no significant differences in the 
detection of Candida tropicalis (p = 0.125) and Candida glabrata (p = 1.000) utilizing both 
methods. Candida albicans, C. parapsilosis, C. glabrata and Malassezia sympodialis were 
detected by both methods, however, most frequently detected molecularly.  
 
4.4 Results related to Aim 3 
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The third aim of this thesis (Aim 3) was to compare cultivable fungi in saliva and mucosa. Since 
we detected very low number of fungi in saliva, we reasoned that perhaps higher numbers could 
be seen if a different oral site was sampled. For the development of this part, we included 24 
subjects in which we were able to collect and analyze both saliva and swab samples.  
 
There was not a significant difference (p = 0.289) in the percentage of sample positive for fungi 
when comparing saliva and swabs (Figure 12) 
 
 
Figure 12. Percentage samples positive in saliva versus swabs. Differences were evaluated via 
McNemar test. 
 
Total abundance of salivary and mucosal fungi is represented in Tables 10 and 11.  
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Table 10. Salivary fungi detected via cultivation. Data represent total abundance.  
 
 
Table 11. Mucosal fungi detected via cultivation. Data represent total abundance. 
 
We then analyzed the data at the genus level to determine how many subjects were positive 
for each specific genus. From the seven genera detected utilizing both methods, swab samples only 
allowed detection of five out of seven genera, compared to saliva which resulted in positives in six 
out of seven. None of the genera detected were significantly different by either of the methods 
employed. (Figure 13) 
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Figure 13. Prevalence of genera in saliva vs swab. Data represent percentage of subjects positive.  
Differences were evaluated via McNemar test. 
 
We also analyzed the data at the species level to determine how many subjects were 
positive for each specific species. From the ten-species detected utilizing both methods, swab 
samples were positive for seven species compared to saliva samples which were positive for nine 
species. None of the species detected were significant for either of the methods employed. 
(Figure 14) 
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Figure 14. Prevalence of species of Candida and Malassezia in saliva and swab. Data represent 
percentage of subjects positive.  Differences were evaluated via McNemar test. 
 
Overall, these results confirm that the recovery of fungal species from saliva samples is 
comparable to mucosal swabs. As an important point to consider is that the prevalence for any of 
these taxa obtained via cultivation methods was below 50%. 
 
4.5 Ability of cultivation to detect molecular mycotypes  
 Since via cultivation, we did not detect Candida and Malassezia together in the same 
individual, we next compared the ability of cultivation to separate patients into mycotypes (as 
detected molecularly). 
 
 As can be seen, if a subject is positive in either saliva or swab for Candida it is very likely 
that this subject belongs to the Candida mycotype as determined molecularly (Sensitivity = 1; 
Specificity = 0.91) 
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Table 12. Sensitivity and Specificity of the ability of cultivation to detect molecular mycotypes  
   MOLECULAR 
   Candida Mycotype 
   (+) (-) 
CULTIVATION 
Candida Mycotype (+) 12 1 
(Saliva and swab) (-) 0 10 
   Sensitivity Specificity 
   1 0.91 
 
   MOLECULAR 
   Candida Mycotype 
   (+) (-) 
CULTIVATION 
Candida Mycotype (+) 11 1 
(Saliva ) (-) 1 10 
   Sensitivity Specificity 
   0.92 0.91 
 
   MOLECULAR 
   Candida Mycotype 
   (+) (-) 
CULTIVATION 
Candida Mycotype (+) 11 0 
(Swab ) (-) 1 11 
   Sensitivity Specificity 
   0.92 1 
 
 
   MOLECULAR 
   Malassezia Mycotype 
   (+) (-) 
CULTIVATION 
Malassezia Mycotype (+) 4 0 
(Saliva and Swab ) (-) 7 12 
   Sensitivity Specificity 
   0.36 1 
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   MOLECULAR 
   Malassezia Mycotype 
   (+) (-) 
CULTIVATION 
Malassezia Mycotype (+) 2 0 
(Saliva ) (-) 9 12 
   Sensitivity Specificity 
   0.18 1 
 
   MOLECULAR 
   Malassezia Mycotype 
   (+) (-) 
CULTIVATION 
Malassezia Mycotype (+) 2 0 
(Swab ) (-) 9 12 
   Sensitivity Specificity 
   0.18 1 
 
4.6 Association of fungi and collected clinical data 
 
Table 13. Correlation between Mycotype, fungal load as determined via cultivation or relative 
abundance of Candida and Malassezia spp. with collected clinical data. Spearman correlation 
tests were used.  
 
p	<	0.05
Number	of Presence	of Patient	has	a	Prosthesis Number	of	teeth Number	of	teeth Total	of	number	of	teeth	replaced
teeth	w/caries Caries (fix	and/or	removable) replaced	w/fixed replaced	w/removable by	prosthetis	(including	F	or	R)
r	(p) r	(p) r	(p) r	(p) r	(p) r	(p) r	(p) r	(p) r	(p) r	(p)
Mycotype NS NS NS 0.454	(0.030) NS NS NS NS NS NS
C.	albicans	CFU/mL NS NS NS 0.430	(0.041) NS NS NS NS NS NS
C.	parapsilosis	CFU/mL -0.530	(0.009) NS NS 0.423	(0.044) NS -0.477	(0.022) NS NS NS -0.437	(0.037)
C.	glabrata	CFU/mL NS NS NS NS NS NS NS NS 0.438	(0.037) NS
Candida	total	load NS NS NS 0.605	(0.002) 0.434	(0.38) NS NS NS NS NS
Candida	Relative	Abundance NS NS NS NS NS NS NS NS NS NS
Malassezia	Relative	Abundance NS -0.497	(0.16) NS -0.439	(0.36) NS NS NS NS NS NS
C.	albicans	Relative	Abundance NS NS NS NS NS NS NS NS NS NS
C.	parapsilosis	Relative	Abundance -0.600	(0.002) NS NS NS NS -0.599	(0.003) -0.545	(0.007) -0.624	(0.001) NS -0.474	(0.22)
C.	glabrata	Relative	Abundance NS NS NS NS NS NS NS NS NS NS
M.	restricta	Relative	Abundance NS -0.437	(0.37) NS -0.507	(0.14) NS NS NS NS NS NS
M.	sympodialis	Relative	Abundance NS NS NS NS NS NS NS NS NS NS
M.	globosa	Relative	Abundance NS NS NS NS NS NS NS NS NS NS
M.	sympodialis	CFU/mL NS NS NS NS NS NS NS NS NS NS
E.	dermatitidis	CFU/mL NS NS NS NS NS NS NS NS NS NS
P.	guillermondii	CFU/mL NS 0.482	(0.020) -0.421	(0.046) 0.446	(0.033) NS NS NS NS NS NS
R.	mucilaginosa	CFU/mL NS NS NS NS NS NS NS NS NS NS
R.	sp.	LK1110	CFU/mL NS NS NS NS NS NS NS NS NS NS
C.	albidosimilis	CFU/mL NS NS NS NS NS NS NS NS NS NS
Total	CFUs NS NS NS 0.594	(0.003) 0.463	(0.026) NS NS NS NS NS
Age Female White Fixed	prosthesis
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 We found also a positive correlation in patients with Candida Mycotype and number of 
teeth with caries. Also, the total abundance of C. albicans, C. parapsilosis, P. guillermondii, total 
fungal abundance and total Candida abundance were positively correlated with number of caries. 
Molecularly, Malassezia relative abundance and M. restricta relative abundance were negative 
correlated with number of caries.  
 
 Candida parapsilosis was found negative correlated with age, patients with fixed or 
removable prosthesis and total number of teeth replaced either by fixed or removable prosthesis. 
Candida glabrata was positive correlated with number of teeth replaced by removable prosthesis.   
 
4.7 Description of fungal colonies obtained on CHROMagarTM Malassezia.  
  
Since no previous study has reported isolation of oral fungi in CHROMagarTM Malassezia, we 
include here a description of the colonies obtained.  
 
4.7.1. Candida albicans 
 Well defined green color, it has a green halo imprinted in the agar. Shiny, regular 
borders, 1.5mm diameter at the second day. 
A  B  
Fig. 15 CFU view (A) and plate view (B) at second day of inoculation. 
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4.7.2. Candida parapsilosis 
 Well defined pink color. Shiny, regular borders, 1 mm diameter at second day. It changes 
at the fourth day getting darker in its core, surrounded by a light pink color halo and increasing 
its diameter to 4mm approximate, shiny and slight irregular borders.  
A   B  
Fig.16 CFU view at second day (A) and fourth day (B) of inoculation. 
 
 
4.7.3. Candida glabrata 
 Dark pink in its core, surrounded by a light pink color halo, 3mm diameter approximate, 
shiny with regular borders at the third day. 
 
Fig. 17 CFU view at third day of inoculation. 
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4.7.4. Malassezia sympodialis 
 Well defined dark purple color. Mate, regular borders, 1mm diameter at the 4th day. 
 
Fig. 18 CFU view at fourth day of inoculation. 
 
4.7.5. Pichia guillermondii 
 Well defined pink color. Shiny, regular borders, 1mm diameter at the second day. 
 
Fig. 19 CFU view at second day of inoculation. 
 
4.7.1. Rhodotorula mucilaginosa 
 Well defined dark pink, shiny rounded appearance, 1 mm diameter approximate at the 
second day. In some cases, at the fourth day, either the CFU remains the same as described at the 
second day or it might change its morphology to a more corrugated texture including the 
appearance of rings around it and increasing its size to 3 mm diameter approximate.  
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Fig.20 CFU view at the second day (A) and at fourth day (B) of inoculation. 
 
4.7.2. Rhodotorula sp. LK1109 
 Pink color. Shiny, regular borders, very small diameter, approximate 0.2mm diameter at 
the second day.  
A    B  
Fig. 21 CFU view (A) and plate view (B) at second day of inoculation. 
 
4.7.3. Cryptococcus albidosimilis 
 Pink color. Shiny, regular borders, approximate 2mm diameter at the third day. 
A   B  
Fig. 22 CFU view(A) and plate view (B) at third day of inoculation. 
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4.7.4. Exophiala dermatitidis 
 Dark green color. Shiny, regular borders, 1mm diameter at the fourth day. 
 
Fig. 23 CFU view at fourth day of inoculation. 
 
4.7.5. Clavispora lusitaniae 
 No photo available. 
 
5. Discussion 
 Recent studies of the oral mycobiome based on ITS1 sequencing revealed very 
diverse fungal communities 4 5. Among the most abundant taxa reported is Malassezia, however, 
this taxon has never been recovered by cultivation. We chose CHROMagarTM Malassezia for our 
cultivation studies, as this medium has been shown to allow recovery of 9 species of Malassezia 
14
. Indeed, we successfully cultivated ATCC strains of Malassezia restricta ATCC® MYA-
4611TM, Malassezia sympodialis ATCC® 96803TM and Malassezia globosa ATCC® MYA-
4612TM using this medium.  
 
CHROMagarTM Malassezia also allows detection of Candida albicans, Candida glabrata, 
Candida tropicalis, Candida krusei and Candida parapsilosis, and therefore, since we expected 
Candida and Malassezia to be the most abundant oral fungal taxa this medium was an appropriate 
choice. Unexpectedly, this medium also allowed recovery of other oral fungi such as Pichia 
guillermondii, Rhodotorula spp., Cryptococcus albidosimilis, Exophiala dermatitidis, and 
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Clavispora lusitaniae, thereby allowing the comparison of the recovery of these species via 
cultivation and molecular detection. 
 
For the first time, a member of the Malassezia genus has been recovered from the oral 
cavity via cultivation methods. Although Malassezia sympodialis was found in five subjects in the 
present study, we were not able to recover Malassezia restricta and Malassezia globosa which 
were very prevalent and abundant molecularly. One possibility is that these two species were not 
viable cells at the time of cultivation. Since these fungi are also abundant in the skin, there is a risk 
of contamination if the patient bites his/her nails for example. Besides, the recovery of M. 
sympodialis was not consistent utilizing both sampling methods (saliva and mucosa) and it was 
recovered only from one patient in both sites. The low load of Malassezia in the mouth could make 
its growth more difficult compared to Candida which was found in higher abundance. Another 
important potential factor was the temperature we used, since it has been shown that fungi growth 
changes at different temperatures. In addition, the media we used may not be favorable for other 
fungi to growth. 
 
In this study, we were able to detect up to ninety-six genera from a single individual, while 
using cultivation methods we could not recover more than seven genera. New technologies have 
been a very effective way to explore the human mycobiome and certainly have shown us a rich 
variety of fungi species in the mouth. However, cultivation studies are still important to determine 
if these microbes are real living residents of the mouth. The oral mycobiome and its participation 
in different diseases is not completely understood and the literature has prioritized the study of the 
most prevalent species recovered by traditional cultivation methods in the mouth, which it does 
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make sense, but neglected in investigated those called “difficult or non-cultivable fungi” which 
require different cultivation methods and may be present in the mouth too. 
 
Although this study was not powered to compare the cancer arm versus the non-cancer 
arm, we still tried to compare them in a pilot manner. The main difference between the two arms 
was the enrichment of Rhodotorula spp and Candida parapsilosis in the non-cancer arm and this 
is comparable with the results from Monteiro da Silva et al. (2014) who found in forty healthy 
individuals a high prevalence of Rhodotorula spp. (75%) and in subjects who the authors 
denominated “moderate Candida carriers”, they also found C. parapsilosis as one of the most 
prevalent Candida species.  11 Candida parapsilosis seems to be present in general and oral health, 
as it was found in non-cancer and its depletion when patients increased in age and wearers of fixed 
or removable prosthesis.  
 
In the cancer arm, we reported similar results to Epstein et al (1993) study in which they 
found the presence of pseudomembranous candidiasis associated to radiation therapy was very low 
(one out of 27 patients). In our study, only four of our patients were receiving or had a history of 
head and neck radiation therapy at the time of sample collection and none of them developed oral 
candidiasis 16. Oral mucositis was more prevalent in our study. We reported a patient who was 
undergoing chemotherapy and was a carrier of C. albicans and also has a high abundance of C. 
glabrata. This result is compatible with Schelenzn et al. (2011) who found C. glabrata as the 
second most common colonizing species (besides to C. albicans) in the mouth of patients with 
cancer.42 
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Another interesting finding was the clustering of two groups based in a particular genus 
dominancy of the oral cavity. These two-dominant genera were either Candida or Malassezia. This 
finding agrees with what it was found by Diaz et al (unpublished data), study in which the authors 
also found the dominancy of these two genera in 59 subjects using saliva samples via molecular 
detection. Via cultivation methods, we had more subjects positive for fungi (75%) compared to 
Young et al. (1951) study, however Candida albicans was the most the prevalent in both studies, 
and in both studies it was recovered in approximately half of the total studied population, 
suggesting as well that the rest of the population could be dominated by another 
uncultivable/difficult to cultivate fungus such as Malassezia 10. Furthermore, in this study, we 
reported a strong correlation of the Mycotype Candida with number of dental caries. Also, we were 
able to use effectively CHROMagar Malassezia media to identify patient carriers of this Mycotype.  
 
The existence of sub-mycotypes of Malassezia spp. based on its location in the human 
body has been described by Theelen et al. (2018). 25 Some studies refer the posterior part of the 
tongue as more abundant for Candida spp. colonization. 43 However, not much has been described 
regarding patterns of colonization of fungi (including Malassezia spp) in the oral cavity for 
example. For this study, we employed only saliva samples and mucosal swabs which did not 
discriminate from specific areas within the oral cavity, but this may open a door for a future 
investigation.  
 
6. Conclusion 
 We report for first time the cultivation of Malassezia from oral samples utilizing a lipid 
enriched media confirming its presence as a viable oral mycobiome member. However, while 
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Malassezia was detected by molecular methods in all patients, it was only seen via cultivation in 
five subjects, and the only Malassezia species recovered was M. sympodialis.   
  
 Malassezia does not appear to be enriched in subjects undergoing cancer treatment and its 
colonization (detected via cultivation) did not vary between saliva and mucosa. Other oral fungi 
such as Candida appear to be also important components of the oral mycobiome. We also report 
the recovery via cultivation of other fungal taxa such as Pichia guillermondii, Rhodotorula sp. 
LK1109, Cryptococcus albidosimilis, Exophiala dermatitidis, and Clavispora lusitaniae. Apart 
from Candida spp. which can reach cultivable levels up to 4 x 104, the load of other oral fungi, 
including Malassezia appears to be very low. Nevertheless, we found a strong correlation between 
number of caries and the mycotype Candida. In addition, the use of CHROMagar Malassezia 
allowed us to determine with high sensitivity and specificity if the patient belongs to the mycotype 
Candida. Thus, this medium could perhaps be utilized to assess patient’s risk for caries. However, 
this needs to be studied in a longitudinal manner and in a larger population. 
 
 Future studies should determine the importance of these fungal communities present in low 
abundance in oral homeostasis.  
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